Biotechnology

Vera Therapeutics

NVIDIA

Conference Minutes

MSFT

002245

OpenAI

DXYZ

NVDA

VERA

ORCL

GPUS

MSFL

MSFO

MSFD

MSFU

MSFX

MSFY

NVDL

07788

07388

NVDY

GPUS-D

<p>The following are the minutes of NVIDIA's FY2026 Q3 earnings call, compiled by Dolphin Research. For an interpretation of the earnings report, please refer to the article 'More Important Than Non-Farm Payrolls! Can NVIDIA Save the US Stock Market Again?' Compared to the earnings report, the information conveyed in this earnings call is more critical: ① Data Center Revenue: GB300 sales surpassed GB200, contributing about two-thirds of Blackwell's total revenue. Hopper revenue was approximately $2 billion, with H20 accounting for about $50 million; Regarding guidance: the company provided revenue guidance for the next quarter...</p>

Microsoft

Jiangsu Azure Corporation

ISHRS S Arabia

Target

Destiny Tech100

Oracle

Hyperscale Data

GraniteShares 2x Long MSFT Daily ETF

YieldMax MSFT Option Income Strategy ETF

Direxion Daily MSFT Bear 1x Shares

Direxion Daily MSFT Bull 2X Shares

T-Rex 2X Long Microsoft Daily Target ETF

Kurv Yield Premium Strategy Microsoft MSFT ETF

GraniteShares 2x Long NVDA Daily ETF

XL2CSOPNVDA

XI2CSOPNVDA

YieldMax NVDA Option Income Strategy ETF

HYPERSCALE DATA INC 13.00%CUM RED PER PREF STK SER D USD25

NVIDIA (Minutes): Target gross margin for next year is 75%, collaboration with OpenAI is not blind

Evercore ISI Analyst Maintains Buy Rating on Vera Therapeutics

Vera Therapeutics Inc. Director Buys Company Shares

Wedbush Maintains Hold Rating on Vera Therapeutics with a Target Price of $33.00

Vera Therapeutics Inc. Chief Regulatory Officer Disposes of Common Stock

Vera Therapeutics Prices Public Offering of Shares

TD Cowen Maintains Vera Therapeutics Buy Rating and Raises Target Price to $73

William D. Turner Sells Vera Therapeutics Common Stock

Analysts Maintain Buy Rating for Vera Therapeutics

Vera Therapeutics Submits BLA for Atacicept to FDA

Vera Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2599 (forecast USD -1.1766)

Vera Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST), with actual revenue of USD 0 and EPS of USD -3.2692

Rami Katkhuda Maintains Buy Rating on Vera Therapeutics

Vera Therapeutics to Present Atacicept Phase 3 Clinical Data for IgA Nephropathy at 2025 ASN Kidney Week

Vera Therapeutics ORIGIN 3 abstract selected for oral presentation at 2025 ASN Kidney Week

Vera Therapeutics to present atacicept Phase III trial data at ASN Kidney Week 2025

Stavropoulos Maintains Strong Buy Rating on Vera Therapeutics Stock

Clark-Gartner Rates Vera Therapeutics Strong Buy with a Target Price

Vera Therapeutics released FY2025 Semi-Annual earnings on August 5 (EST), actual revenue USD 0, actual EPS USD -2.0119

Vera Therapeutics released FY2025 Q2 earnings on August 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2 (forecast USD -0.702)